Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosolized vs IV Colistin in COVID-19 with Bacterial Coinfection
NCT05689229Phase 3Completed
- Sponsor
- Beni Suef University
- Start
- Aug 2021
- Primary completion
- Nov 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of colistin in Gram-negative bacterial infection (3 arms), sponsored by Beni Suef University. Primary endpoints: Microbial eradication at 10 days and Mortality at 30 days. Started Aug 2021; status: completed.
02
Drugs
colistin
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT05689229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05689229.